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ABSTRACT
Background: Reconfirming the diagnosis of childhood onset growth hormone deficiency
(GHD) in young adults is necessary to demonstrate the need for continuation of GH therapy.
Objective: This nationally–based study was planned to establish GH status during adulthood in child-
hood-onset GH deficient patients and to evaluate factors that would predict persistency of the GHD.
Methods: In this multicenter study, 70 GH deficient patients who had reached final
height were evaluated after completion of GH treatment. Fifty-two patients (74%) had isolated
GHD and 18 patients (26%) had multiple pituitary hormone deficiency (MPHD). Patients who had
reached final height and the pubertal Tanner stage 5 were reevaluated for GH status. After at least
6 weeks of cessation of GH treatment, patients were retested with insulin induced hypoglycemia.
Results: GHD was found to be transient in 64.3% of all patients. Of the isolated GH deficient
patients 82.7% had transient GHD, whereas 88.9% of the MPHD patients showed persistent
GHD. Comparison of isolated GH deficient and multiple hormone deficient patients indicated
higher peak GH, IGF-I and IGFBP-3 levels in isolated GH deficient patients. No parameter was sig-
nificantly different in the transiently and persistently GH deficient patients with respect to gen-
der. Although specificity of IGF-I value of less than -2 SD showing persistency of GHD was lower
than the specificity of IGFBP-3 value of less than -2 SD (65.7% vs 84%), negative predictive val-
ues were similar for the two parameters (85.2% and 84%, respectively). 
Conclusion: Most of the cases of childhood onset GHD are idiopathic and the GHD is transient.
In patients with MPHD, GHD is generally permanent. Low IGF-I and IGFBP-3 levels are support-
ing findings to show persistency of the GHD.
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INTRODUCTION
It has been shown in several studies that
a normally functioning hypothalamus-pitu-
itary-insulin like growth factor I (IGF-I) axis
is very important not only in children but
also in adults.
Adult growth hormone deficiency (GHD)
is characterized by decreased lean body mass
(LBM) and bone mineral density (BMD),
increased visceral adiposity, abnormal lipid
profile and diminished quality of life.(1, 2)
Therefore, some patients with childhood-
onset GHD might need to continue growth
hormone (GH) replacement therapy after
attainment of final height. However, most of
the childhood-onset GHD patients, when
retested, do not have classical severe GHD as
adults. The high incidence of normal GH
responses on retesting has been shown in
patients with idiopathic or isolated GHD.(3)
However in patients with multiple pituitary
hormone deficiency (MPHD) and/or organic
etiologies, persistence of severe GHD into
adulthood is more frequent (>90%).(4)
Reconfirmation of the GHD diagnosis will be
necessary in order to demonstrate the need
for continuation of GH therapy.
In this multicenter study we evaluated
GH stimulation tests and serum IGF-I and
IGF binding protein (IGFBP)-3 levels in a
group of patients who had been diagnosed
with GHD in childhood and had reached
final height after GH treatment. The study
aimed to evaluate the frequency of GHD in
adults with previous childhood-onset GHD,
to identify the potential patients for GH
treatment during transition and adulthood.
and also to evaluate factors that would pre-
dict persistent GHD. 
MATERIALS AND METHODS
This study was conducted in five centers
in Turkey. Patients who had been diagnosed
as having idiopathic or organic isolated GHD
or MPHD before the completion of their
growth were included in the study. GHD
diagnosis was based on a peak GH level <10
ng/mL in two pharmacological tests. GH
treatment was discontinued in these patients
when growth velocity during the previous
year decreased to less than 2 cm and the
bone age had reached >14 years in girls, >16
year in boys, and after completion of puber-
ty. GH secretion was reevaluated in a total of
70 (31 F/39 M) subjects who had completed
the pediatric GH treatment protocol. Their
main clinical findings and etiologies are sum-
marized in Table 1 and Figure 1. Data regard-
ing final height will not be discussed in the
present paper. Weight and height were meas-
ured by standard methods and body mass
index (BMI) calculated accordingly.
In all patients GH secretion was reevaluat-
ed by insulin tolerance test (ITT) at least 6
weeks after discontinuation of the replace-
ment treatment. Serum IGF-I and IGFBP-3
concentrations were determined at the same
time. Insulin (0.05 U/kg) was given intra-
venously at time zero and venous blood sam-
ples for GH determination and glucose were
obtained at time 0 and at 30, 60, 90 and 120
minutes after the injection. If GH peak during
the test was less than 3 ng/mL, the patient was
diagnosed to have severe permanent GHD.
Serum GH (ng/mL) levels were measured
by Immunoradiometric assay (IRMA) using
Immunotech® kit. Serum IGF-I (ng/mL) lev-
els were measured by Immunoradiometric
assay (IRMA) using Immunotech® kit and
serum IGFBP-3 (ng/mL) levels were meas-
ured by Immunoradiometric assay (IRMA)
using DSL® kit. 
Statistical analysis was done by using
Minitab® software package program. P<0.05
was considered statistically significant.
Comparisons between groups were per-
formed using Student is t-test. Spearman r
coefficient was used to correlate IGF-I,
IGFBP-3, and peak GH after retesting.
Specificity, sensitivity, positive predictive
value, and negative predictive value of IGF-I
levels of less than -2 SD and IGFBP-3 value
of less than -2 SD were determined by stand-
ard statistical methods. 
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Standard deviation scores (SDS) were
calculated for IGF-I and IGFBP-3 by refer-
ence to a normal population in order to con-
trol for age and gender.(5)
Informed consent was obtained from the
patients.
RESULTS
As seen in Figure 2, 74% of GH defi-
cient patients had isolated GHD. By taking
a peak GH value of less than 3 ng/mL in
the ITT test, 9 patients (17.3%) were found
to have persistent GHD and 43 (82.7%) to
be transiently GH deficient. On the other
hand, among patients with MPHD only 2
patients (11.1%) were transiently GH defi-
cient.
Overall 64.3% of patients were transient-
ly, and 35.7% of patients were persistently
GH deficient. Characteristics of the groups
with isolated GHD or MPHD are shown in
Table 1. Patients who had isolated GHD
achieved their final height at younger ages.
In concordance with a lower peak GH
response, IGF-I and IGFBP-3 levels were sig-
Figure 1: Distribution of the patients by etiology of GHD
Figure 2: GH responses after ITT retest in isolated or multiple GH deficient patientsnificantly lower in the multiple hormone
deficient groups (p<0.05) and inversely,
height improvement was better (Table 1). 
The groups of children with persistent or
transient GHD were subdivided into males
and females. None of the parameters differed
significantly with respect to gender. There
were significant positive correlations between
peak GH and IGF-I, and IGFBP-3 levels in all
patients (Figure 3) (IGF-1 r=0.297, p=0.036;
IGFBP-3 r=0.45, p=0.03).
The IGF-I and IGFBP-3 SDS values were
lower in the group that had peak GH values
lower than 3 ng/mL (Table 2).
When the cut-off was taken as -2 SD,
specificity and sensitivity of IGF-I in confirm-
ing persistency of GHD were 65.7% and 73.3%
respectively. Its positive predictive value and
negative predictive value were 33.3% and
85.2%, respectively. For IGFBP-3, specificity
and sensitivity were 84%, and 60% respective-
ly. The positive value and negative predictive
values were 60%, and 84%, in the same order.
Finally, while the negative predictive values
were high for both of these parameters, an
IGFBP-3 value below -2 SD was found to be
more specific than an IGF-I value below -2 SD.
DISCUSSION
Data from recent studies suggest that in
patients diagnosed to have organic GHD in
childhood, when GH is discontinued at final
height in adolescence, a cascade of symptoms
Table 1: Clinical characteristics of the subjects included in the study
All isolated GHD All MPHD
All patients patients patients P value
n 70 52 18
Age at GH Retesting (yrs) 18.0±3.5 16.8±2.0 21.6±4.5
(13.8 to 28.5) (13.8 to 23.8) (14.3 to 28.5)
Peak GH (ng/mL) 9.6±10.2 12.6±10.2 1.2±2.0
(0.01 to 41.4) (0.1 to 41.4) (0.01 to 6.9)
IGF-I (ng/mL) 414.4±341.9 503.8±324.5 56.9±51.8
(5.6 to 1588) (5.6 to 1588) (7.2 to 171.4)
IGFBP-3 (ng/mL) 4996±2223 5336±2092 2365±1355
(1150 to 9484) (1240 to 9484) (1150 to 4130)
Weight (kg) 49.7±12.2 49.4±12.1 50.6±12.6
(29.9 to 92) (29.9 to 92) (33 to 80)
BMI (kg/m
2) 20.4±3.9 20.0±4.0 21.4±3.6
(14.6 to 35.6) (14.6 to 35.6) (6.5 to 30.5)
Final height SDS -1.6±1.2 -1.4±0.8 -2.2±1.9
(-7.1 to 1.0) (-3.5 to 0.0) (-7.1 to 1.0)
D height SDS* 1.6±1.2 1.5±0.9 2.1±1.8
(-0.7 to 5.4) (-0.01 to 4.1) (-0.7 to 5.4)
Total height gain (cm) 29.8±15.3 26.9±12.3 38.1±19.9
(8 to 83) (10 to 65.8) (8 to 83)
Target height SDS -0.9±0.9 -0.9±0.7 -1.1±1.2
(-2.9 to 1.0) (-2.9 to 0.4) (-2.9 to 1.0)
Final height SDS-Target -0.6±1.0 -0.5±0.8 -0.9±1.3
height SDS (-3.0 to 1.7) (-2.1 to 1.7) (-3.4 to 0.9)
*Final height SDS-height SDS at diagnosis
0.04
0.000
0.000
0.0048
NS
NS
0.007
0.025
0.004
0.22
0.1
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and signs attributable to the deficiency of the
metabolic effects of GH may be experienced
in adulthood.(6) A great number of studies
have shown that the incidence of idiopathic
and isolated GHD is much higher in child-
hood. The majority of children with GHD
when retested as adults do not have the clas-
sical severe GHD.(7) This high incidence
(70%) of normal GH responses on retesting
has been shown in patients with idiopathic
and isolated GHD.(3) In compliance with the
published reports, this study has also shown a
higher proportion of transient GHD (82.7%) in
patients with idiopathic isolated GHD (Figure
2). By contrast, the incidence of transient
GHD was only 11.1% in organic MPHD. This
finding indicates that the organic etiologies
are often severe and can be assumed to be
permanent at the beginning of the therapy.
In this study comparison of patients with
isolated GHD and with MPHD indicated a
better D height SDS and total height gain in
the multiple pituitary hormone deficient
patients. No parameter was statistically signif-
icant when compared on the basis of gender
in patients with transient and persistent GHD.
Our data confirm that there are no auxologi-
cal and clinical signs to predict the transiency
Table 2: IGF-I and IGFBP-3 levels according to peak GH response 
Peak GH IGF-I (ng/mL) IGF-I SDS IGFBP-3 (ng/mL) IGFBP-3 SDS 
response (ng/mL) (mean±SD) (mean±SD) (mean±SD) (mean±SD)
≥10 506.9±242.9 6560±1680
n:28 (200–1032) (4400–9484)
3-10 537±488 3809±1260
n:17 (76–1588) (1980–5560)
<3 170.7±216.8 3563±2124
n:25 (5.6–618.7) (1150–7250)
IGF-I IGFBP-3
Specificity 65.7% 84%
Sensitivity 73.3% 60%
Positive predictive value 33.3% 60%
Negative predictive value 85.2% 84%
-0.9±2.0
-0.8±3.8
-5.2±3.2
1.5±2.3
-2.4±1.7
-2.9±3.0
Figure 3: Correlation between peak GH response and IGF-I and IGFBP-3 levels
Correlation between peak GH (ng/mL) response and IGF- I (ng/mL) level: r=0.297, p=0.036
Correlation beween peak GH (ng/mL) response and IGFBP-3 (ng/mL) level: r=0.45, p=0.03
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IGF-Ior the persistence of GHD except for a histo-
ry of organic disease and presence of MPHD.
Toogood et al(8) have also reported that the
severity of hormone deficiency in adults is
related to the degree of hypopituitarism.
Meanwhile the question of how to con-
firm the diagnosis of adult GHD in an ado-
lescent patient who has completed linear
growth is still being debated.
It is well known that during childhood
and adolescence, GH secretion is higher than
in adulthood. Individual laboratory values of
GH deficient patients can overlap with those
of normal controls. The Growth Hormone
Research Society guidelines suggest a peak
GH response on ITT of less than 3 ng/mL as
being diagnostic of GHD in adulthood.(9) It
is not clear whether this value can confirm
adulthood GHD exactly. Usually patients
with MPHD have peak GH levels less than 3
ng/mL. Hence in our study we used this cut-
off value to confirm permanent deficiency.
On the other hand the patients who had
peak GH cut-off values between 3-5 ng/mL
might be GH deficient as well. In fact, in the
transition period in late adolescence a cut-off
value of 5 ng/mL is advocated for the diag-
nosis of persistent GHD and continuation
GH therapy because adolescents have high-
er GH levels than adults.(7) In our study the
3 additional patients with peak GH level
between 3-5 ng/mL in the isolated GHD
group in late adolescence can be considered
as candidates for GH therapy in the transition
period. There were no similar cases in the
MPHD group. The prognosis of patients with
a GH response of 5-10 ng/mL is not known.
However, deterioration of GH secretion can
occur in this group therefore it may be advis-
able to follow these patients.(10)
In adults ITT appears to be the gold stand-
ard test of choice.(9, 11) Because of the risks
associated with hypoglycemia, currently
GHRH-arginine test is an alternative to
ITT.(12) Because of the difficulties in finding
GHRH in our country, we performed ITT on
all patients in experienced centers. 
In young adults in whom retesting is nec-
essary, a period off GH is required before
testing. Consensus statements and clinical
practice guidelines suggest 1-3 months
between GH discontinuation and retest-
ing.(13) In this study we retested at least 6
weeks after GH discontinuation. The optimal
duration of washout before retesting serum
GH and IGF-I, IGFBP-3 levels are not clear.
Longer period may be risky in the follow-up
of those adolescent patients.
Zucchini et al showed that one third of
GHD subjects diagnosed before puberty pre-
sented with normal GH secretion at puberty.
According to this study, puberty seems the
most likely time for normalization of GH
secretion. In all patients we performed retest-
ing after completion of puberty.
IGF-I levels are not useful as the sole
diagnostic test for many GH deficient
patients. Levels vary between and within
individuals and may not be helpful for mak-
ing a definitive diagnosis of persistent GHD.
However, in contrast to patients with adult
onset GHD, very few patients with child-
hood-onset GHD have IGF-1 or IGFBP-3
levels within normal ranges.(15) In compli-
ance with the published reports, there were
significant positive correlations between
peak GH and IGF-I, and IGFBP-3 levels in
all our childhood onset GH deficient
patients. Lower GH response and lower IGF-
I, and IGFBP-3 levels in multiple pituitary
hormone deficient groups appear to be char-
acteristic of any degree of childhood onset
hypopituitarism. Furthermore lower IGF-I
and IGFBP-3 SDS values are associated with
the persistent GHD group who had peak
GH response below 3 ng/mL. In our study
the specificity of IGF-I for persistent GHD
was lower than of IGFBP-3 (65.7% vs. 84%),
However, negative predictive values were
higher and similar for these two parameters
(85.1% and 84% respectively). This finding
means that normal IGF-I and IGFBP-3 levels
highly exclude the diagnosis of GHD. Baum
et al showed that no patient with GHD had
IGF-I levels in the upper half of the normal
range. On the other hand, based on speci-
ﬁ›klar Z. et al
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ficity and sensitivity values, the use of serum
IGF-I and IGFBP-3 alone to predict GHD
cannot be recommended. Nevertheless,
those patients with organic MPHD could be
excluded from retesting.
In conclusion, most patients with
childhood onset GHD are idiopathic and
GHD is frequently transient in this group
of patients. Generally GHD is persistent
in patients with MPHD. We strongly offer
retesting of all patients with idiopathic
and isolated GHD patients to identify
transient patients after they have reached
their final height. Low IGF-I and IGFBP-3
levels are supportive findings to show
persistency and severity of GH deficiency.
It appears that only longitudinal follow-
up can demonstrate those patients who
may or may not need GH treatment in
adult life.
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